Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Amit Etkin M.D., Ph.D. | Founder, Chairman of the Board, CEO & President | 996k | -- | 1977 |
| Mr. Nicholas C. Smith | CFO & Chief Business Officer | 680.47k | -- | 1989 |
| Mr. Michael C. Hanley M.B.A. | Chief Operating Officer | 623.01k | -- | 1973 |
| Mr. Dan Segal B.Sc. (Hons), BCom, CA, MSc | Co-Founder & Strategic Advisor | -- | -- | 1962 |
| Ms. Erin R. McQuade J.D. | General Counsel, Chief Administrative Officer & Corporate Secretary | -- | -- | 1975 |
| Mr. Adam Savitz M.D., Ph.D. | Chief Medical Officer | 579.57k | -- | 1966 |
| Ms. Jessica Powell | Chief Development Officer | -- | -- | 1975 |
Alto Neuroscience, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 76
Description
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
February 7, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission